ReviewVaccines2023
Vaccine Candidates against Arenavirus Infections.
Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Respiratory mucosal vaccines for emerging viruses: promise and challenges.Journal of virology · 2026Review
- Immunogenicity of recombinant vesicular stomatitis virus-vectored vaccines expressing the Machupo virus glycoprotein in different genome positions.Journal of virology · 2026Article
- Computational Design of a Broad-Spectrum Multi-Epitope mRNA Vaccine Candidate for Mammarenaviruses.Applied biochemistry and biotechnology · 2026Article
- Development and protective evaluation of mRNA vaccines encoding the glycoprotein precursor of lymphocytic choriomeningitis virus.Virus research · 2026Article
- Development of novel monoclonal antibodies for detection of pan-Lassa virus.PLoS neglected tropical diseases · 2026Article
- Immunoinformatics-driven design of a multi-epitope vaccine for effective protection against Machupo virus.Molecular diversity · 2026Article
- Immunoinformatic based designing of highly immunogenic multi-epitope subunit vaccines to stimulate an adaptive immune response against Junin virus.Molecular diversity · 2025Article
- Safety Toxicology Study of Reassortant Mopeia-Lassa Vaccine in Guinea Pigs.Future pharmacology · 2025Article
- Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.EBioMedicine · 2025Article
- Review
- Article
- Development of Effective Medical Countermeasures Against the Main Biowarfare Agents: The Importance of Antibodies.Microorganisms · 2024Review
- A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs.NPJ vaccines · 2024Article
- Characterization of bi-segmented and tri-segmented recombinant Pichinde virus particles.Journal of virology · 2024Article
- Strategies of rational and structure-driven vaccine design for Arenaviruses.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2024Review
- The Adaptive Immune Response againstViruses · 2024Review
- Entry inhibitors as arenavirus antivirals.Frontiers in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The viral family
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.